

Inhibikase Therapeutics, Inc.  
3350 Riverwood Parkway, Suite 1900  
Atlanta, GA 30339

October 30, 2020

VIA EDGAR  
Securities and Exchange Commission  
Division of Corporation Finance  
Office of Life Sciences  
100 F Street, N.E.  
Washington, D.C. 20549-3720

Attention: Rolf Sundwall  
Sasha Parikh  
Abby Adams  
Suzanne Hayes

Re: Inhibikase Therapeutics, Inc.  
Registration Statement on Form S-1  
SEC File No. 333-240036

Ladies and Gentlemen:

Reference is made to that certain letter, filed as correspondence via EDGAR on October 27, 2020, in which Inhibikase Therapeutics, Inc. (the "**Company**") requested that the effective date of the Company's Registration Statement on Form S-1 (File No. 333-240036) (the "**Registration Statement**") be accelerated so that the Company's Registration Statement would become effective on Thursday, October 29, 2020, at 5:00 p.m. (Eastern Time), or as soon thereafter as practicable. The undersigned is no longer requesting that the Registration Statement become effective at this time and hereby formally withdraws such request.

**INHIBIKASE THERAPEUTICS, INC.**

By: /s/ Milton H. Werner, Ph.D.

Name: Milton H. Werner, Ph.D.

Title: President, Chief Executive Officer

Cc: Merrill M. Kraines, Troutman Pepper Hamilton Sanders LLP

---